Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.
Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.
Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, PA, Pfizer spokesman Dean Mastrojohn sent back a confirmation, later declining to specify just how many jobs are being cut.
Pfizer may have FDA approval for meningitis B vaccine Trumenba, but it can only take the jab so far without a nod from the CDC's Advisory Committee on Immunization Practices (ACIP). Now, though, it's got some positive new data on the shot just in time to help it make its case for one.
An early FDA approval is a bonus for any drug. But for Pfizer's new breast cancer drug Ibrance (palbociclib), the earlier-than-expected green light has given it a billion-dollar-plus boost--on paper, anyway.
In a study published in JAMA on Tuesday, researchers said Chantix helped smokers who'd like to stop but weren't yet ready to quit get serious about the idea. The study authors estimated that 14 million current smokers fit the same profile as the study participants. That's a lot of potential new patients.
Rare disease specialist Genzyme talked up the results of a study published in The Journal of the American Medical Association concluding that the only first-line oral therapy for Gaucher disease reduced spleen size 28% compared to placebo after 9 months.
Pharma bigwig Pfizer announced that the FDA has agreed to review the New Drug Application of its abuse-deterring extended-release opioid capsules, dubbed ALO-02.
Hospira said on Tuesday that it was recalling more than 60 lots of the pain reliever ketorolac tromethamine injection in the U.S. and Singapore just 5 days after Pfizer said it would pay $15 billion for the specialist in sterile injectable drugs. In fact, on the day the deal was announced, the FDA announced a Hospira recall of the sedative propofol.